Literature DB >> 11404403

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

D Praticò1, K Uryu, S Leight, J Q Trojanoswki, V M Lee.   

Abstract

Oxidative stress is a key feature in the Alzheimer's disease (AD) brain and manifests as lipid peroxidation (LPO). Isoprostanes (iPs) are specific and sensitive markers of in vivo LPO. To determine whether amyloid beta (Abeta) deposition in vivo is associated with increased LPO, we examined iP levels in a transgenic mouse model (Tg2576) of AD amyloidosis. Urine, plasma, and brain tissues were collected from Tg2576 and littermate wild-type (WT) animals at different time points starting at 4 months of age and continuing until 18 months of age. Levels of urinary 8,12-iso-iPF(2alpha)-VI were higher in Tg2576 than in WT animals as early as 8 months of age and remained this high for the rest of the study. A similar pattern was observed for plasma levels of 8,12-iso-iPF(2alpha)-VI. Homogenates from the cerebral cortex and hippocampus of Tg2576 mice had higher levels of 8,12-iso-iPF(2alpha)-VI than those from WT mice starting at 8 months of age. In contrast, a surge of Abeta 1-40 and 1-42 levels as well as Abeta deposits in Tg2576 mouse brains occurred later, at 12 months of age. A direct correlation was observed between brain 8,12-iso-iPF(2alpha)-VI and Abeta 1-40 and 1-42. Because LPO precedes amyloid plaque formation in Tg2576 mice, this suggests that brain oxidative damage contributes to AD pathogenesis before Abeta accumulation in the AD brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404403      PMCID: PMC6762743     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  24 in total

Review 1.  Transgenic mouse models of Alzheimer's disease.

Authors:  C Janus; M A Chishti; D Westaway
Journal:  Biochim Biophys Acta       Date:  2000-07-26

Review 2.  Progress toward valid transgenic mouse models for Alzheimer's disease.

Authors:  S Y Guénette; R E Tanzi
Journal:  Neurobiol Aging       Date:  1999 Mar-Apr       Impact factor: 4.673

3.  Brains of aged apolipoprotein E-deficient mice have increased levels of F2-isoprostanes, in vivo markers of lipid peroxidation.

Authors:  D Praticò; J Rokach; R K Tangirala
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

4.  SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein.

Authors:  C Iadecola; F Zhang; K Niwa; C Eckman; S K Turner; E Fischer; S Younkin; D R Borchelt; K K Hsiao; G A Carlson
Journal:  Nat Neurosci       Date:  1999-02       Impact factor: 24.884

5.  Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo.

Authors:  M A Pappolla; Y J Chyan; R A Omar; K Hsiao; G Perry; M A Smith; P Bozner
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

6.  Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity.

Authors:  D Praticò; C M Clark; V M Lee; J Q Trojanowski; J Rokach; G A FitzGerald
Journal:  Ann Neurol       Date:  2000-11       Impact factor: 10.422

Review 7.  The measurement and mechanism of lipid peroxidation in biological systems.

Authors:  J M Gutteridge; B Halliwell
Journal:  Trends Biochem Sci       Date:  1990-04       Impact factor: 13.807

Review 8.  Antioxidants, oxidative stress, and degenerative neurological disorders.

Authors:  R A Floyd
Journal:  Proc Soc Exp Biol Med       Date:  1999-12

Review 9.  Oxidative alterations in Alzheimer's disease.

Authors:  W R Markesbery; J M Carney
Journal:  Brain Pathol       Date:  1999-01       Impact factor: 6.508

10.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43).

Authors:  S A Gravina; L Ho; C B Eckman; K E Long; L Otvos; L H Younkin; N Suzuki; S G Younkin
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

View more
  242 in total

1.  Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein.

Authors:  Anthony R White; Gerd Multhaup; Denise Galatis; William J McKinstry; Michael W Parker; Rüdiger Pipkorn; Konrad Beyreuther; Colin L Masters; Roberto Cappai
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

2.  Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis.

Authors:  Kunihiro Uryu; Helmut Laurer; Tracy McIntosh; Domenico Praticò; Daniel Martinez; Susan Leight; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

3.  Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery.

Authors:  John Q Trojanowski
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

4.  Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer's disease.

Authors:  A-Ryeong Gwon; Jong-Sung Park; Thiruma V Arumugam; Yong-Kook Kwon; Sic L Chan; Seol-Hee Kim; Sang-Ha Baik; Sunghee Yang; Young-Kwang Yun; Yuri Choi; Saerom Kim; Sung-Chun Tang; Dong-Hoon Hyun; Aiwu Cheng; Charles E Dann; Michel Bernier; Jaewon Lee; William R Markesbery; Mark P Mattson; Dong-Gyu Jo
Journal:  Aging Cell       Date:  2012-04-09       Impact factor: 9.304

Review 5.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?

Authors:  Barry Halliwell; Matthew Whiteman
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

6.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

7.  5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease.

Authors:  Omidreza Firuzi; Jiamin Zhuo; Cinzia M Chinnici; Thomas Wisniewski; Domenico Praticò
Journal:  FASEB J       Date:  2007-11-12       Impact factor: 5.191

Review 8.  Oxidative stress signaling in Alzheimer's disease.

Authors:  B Su; X Wang; A Nunomura; P I Moreira; H-gon Lee; G Perry; M A Smith; X Zhu
Journal:  Curr Alzheimer Res       Date:  2008-12       Impact factor: 3.498

9.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.

Authors:  Syaun Sung; Hengxuan Yang; Kunihiro Uryu; Edward B Lee; Lei Zhao; Diana Shineman; John Q Trojanowski; Virginia M-Y Lee; Domenico Praticò
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 10.  Zinc and its effects on oxidative stress in Alzheimer's disease.

Authors:  Ye Yuan; Fenglan Niu; Ya Liu; Na Lu
Journal:  Neurol Sci       Date:  2014-02-13       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.